A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity (vol 138, pg 237, 2019): A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity (Acta Neuropathologica, (2019), 138, 2, (237-250), 10.1007/s00401-019-02026-8)

Sven J. van der Lee, Erik van den Akker, Najada Stringa, Marc Hulsman, Niccolo Tesi, P. Alexopoulos, G. Rossi, J. van der Zee, Marcel J.T. Reinders, More Authors

Research output: Contribution to journalComment/Letter to the editorScientificpeer-review

Abstract

The IPDGC (The International Parkinson Disease Genomics Consortium) and EADB (Alzheimer Disease European DNA biobank) are listed correctly as an author to the article, however, they were incorrectly listed more than once.

Original languageEnglish
Pages (from-to)959-962
Number of pages4
JournalActa Neuropathologica
Volume139
Issue number5
DOIs
Publication statusPublished - 2020

Fingerprint Dive into the research topics of 'A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity (vol 138, pg 237, 2019): A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity (Acta Neuropathologica, (2019), 138, 2, (237-250), 10.1007/s00401-019-02026-8)'. Together they form a unique fingerprint.

Cite this